GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitro International (OTCPK:IVRO) » Definitions » Debt-to-Asset

Invitro International (Invitro International) Debt-to-Asset : 0.00 (As of Jun. 2097)


View and export this data going back to 1991. Start your Free Trial

What is Invitro International Debt-to-Asset?

Invitro International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2097 was $0.00 Mil. Invitro International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2097 was $0.00 Mil. Invitro International's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2097 was $1.15 Mil. Invitro International's debt to asset for the quarter that ended in Jun. 2097 was 0.00.


Invitro International Debt-to-Asset Historical Data

The historical data trend for Invitro International's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitro International Debt-to-Asset Chart

Invitro International Annual Data
Trend Feb90 Feb91 Sep92 Sep93 Sep94 Sep95 Sep96
Debt-to-Asset
Get a 7-Day Free Trial - - - - -

Invitro International Quarterly Data
Sep92 Dec92 Mar93 Jun93 Sep93 Dec93 Mar94 Jun94 Sep94 Dec94 Mar95 Jun95 Sep95 Dec95 Mar96 Jun96 Sep96 Dec96 Mar97 Jun97
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Invitro International's Debt-to-Asset

For the Diagnostics & Research subindustry, Invitro International's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitro International's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Invitro International's Debt-to-Asset falls into.



Invitro International Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Invitro International's Debt-to-Asset for the fiscal year that ended in Sep. 2096 is calculated as

Invitro International's Debt-to-Asset for the quarter that ended in Jun. 2097 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invitro International  (OTCPK:IVRO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Invitro International Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Invitro International's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitro International (Invitro International) Business Description

Traded in Other Exchanges
N/A
Address
330 East Orangethorpe Avenue, Suite D, Placentia, CA, USA, 92870
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.